In 2013, we published a comparative analysis of mutation and gene expression profiles and drug sensitivity measurements for 15 drugs characterized in the 471 cancer cell lines screened in the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE). While we found good concordance in gene expression profiles, there was substantial inconsistency in the drug responses reported by the GDSC and CCLE projects. We received extensive feedback on the comparisons that we performed. This feedback, along with the release of new data, prompted us to revisit our initial analysis. We present a new analysis using these expanded data, where we address the most significant suggestions for improvements on our published analysisthat targeted therapies and broad cytotoxic drugs should have been treated differently in assessing consistency, that consistency of both molecular profiles and drug sensitivity measurements should be compared across cell lines, and that the software analysis tools provided should have been easier to run, particularly as the GDSC and CCLE released additional data.
Our re-analysis supports our previous finding that gene expression data are Our re-analysis supports our previous finding that gene expression data are significantly more consistent than drug sensitivity measurements. Using new statistics to assess data consistency allowed identification of two broad effect drugs and three targeted drugs with moderate to good consistency in drug sensitivity data between GDSC and CCLE. For three other targeted drugs, there were not enough sensitive cell lines to assess the consistency of the pharmacological profiles. We found evidence of inconsistencies in pharmacological phenotypes for the remaining eight drugs.
Overall, our findings suggest that the drug sensitivity data in GDSC and CCLE continue to present challenges for robust biomarker discovery. This re-analysis provides additional support for the argument that experimental standardization and validation of pharmacogenomic response will be necessary to advance the broad use of large pharmacogenomic screens.
This article is included in the Preclinical gateway. Reproducibility and Robustness 
Box 1. Summary box
In 2013 we reported inconsistency in the drug sensitivity phenotypes measured by the Genomics of Drug Sensitivity in Cancer (GDSC) and the Cancer Cell Lines Encyclopedia (CCLE) studies. Here we revisit that analysis and address a number of potential concerns raised about our initial methodology:
• Different drugs should be compared based on the observed pattern of response. To address this concern, we considered drugs falling into three classes: (1) drugs with no observed activity in any of the cell lines; (2) drugs with sensitivity observed for only a small subset of cell lines; and (3) drugs producing a response in a large number of cell lines. For each class, we assessed the correlation in drug response between studies using a variety of metrics, selecting the metric that performed best in each individual comparison. While no metric identified any substantial consistency for the first class (sorafenib, erlotinib, and PHA−665752) due to no activity, judicious choice of metric found high consistency for three of eight highly targeted therapies in the second class (nilotinib, crizotinib, and PLX4720), but no metric found better than moderate correlation for two of four broad effect drugs in the third class (PD−0332901 and 17-AAG).
• Measure of consistency for targeted drugs. Beyond considering drug response profiles, targeted drugs should be treated differently when assessing consistency. We used six different statistics to test consistency, using both continuous and discretized drug sensitivity data. We confirmed that Spearman rank correlation, used in our 2013 study, does not detect consistency for the three targeted therapies profiled by GDSC and CCLE. Other statistics, such as Somers' Dxy or Matthews correlation coefficient, yielded moderate to high consistency for specific drugs, but there was no single metric that found good consistency for each of the targeted drugs.
• Consistency of molecular profiles across cell lines. In our initial published analysis, we reported correlations based on comparing drug response "across cell lines" while gene expression levels were compared "between cell lines." It has been suggested it would be more appropriate to compute correlations "across cell lines" for both molecular and pharmacological data. Here we report a number of statistical measures of consistency for both gene expression and drug response compared across cell lines and confirm our initial finding that gene expression is significantly more consistent than the reported drug phenotypes.
• Some published biomarkers are reproducible between studies. In our initial comparative study we found that the majority of known biomarkers predictive of drugs response are reproducible across studies. We extended the list of known biomarkers and found that seven out of 11 are significant in GDSC and CCLE. While one can find such anecdotal examples, they do not lead to a general process for discovering a new biomarker in one study that can be applied to another study.
• Research reproducibility. The code we provided with our original paper was incompatible with updated releases of the GDSC and CCLE datasets. We developed PharmacoGx, which is a flexible, open-source software package based on the statistical language R, and used it to derive the results reported here.
Introduction
The goal of precision medicine is the identification of the best therapy for each patient and their own unique manifestation of a disease. This is particularly important in oncology where multiple cytotoxic and targeted drugs are available, but their therapeutic benefits are often insufficient or limited to a subset of cancer patients. Large-scale pharmacogenomics studies in which experimental and approved drugs are screened against panels of molecularly characterized cancer cell lines, have been proposed as a means for identifying drugs effective against specific cancers and for developing genomic biomarkers predictive of drug response. The Genomics of Drug Sensitivity in Cancer project (GDSC, referred to as the Cancer Genome Project [CGP] in our initial study) 1 , and the Cancer Cell Line Encyclopedia (CCLE) 2 have each reported results of such screens, providing data on drug sensitivities and molecular profiles for collections of representative cancer cell lines.
Presented with these two large studies, our hope was that we could use the data to identify new molecular biomarkers of drug response in one study that would predict response in the second. We 3 and others 4-6 reported difficulties in building and validating biomarkers of response using the GDSC and CCLE datasets, even when the analysis was limited to the drugs and cell lines screened in both studies. To understand the cause of this failure, we compared the gene expression profiles and the drug response data reported by the GDSC and CCLE 7, 8 . We found that, although the gene expression data showed reasonable consistency between the two studies, the drug sensitivity measurements were surprisingly inconsistent. This inconsistency can be clearly seen by plotting drug response reported for each of the 15 drugs provided in both GDSC and CCLE for the 471 cell lines assayed by both studies [7] [8] [9] [10] . Since the publication of our comparative analysis, we received a great deal of constructive feedback from the scientific community regarding multiple aspects of the analysis we reported, including suggestions for analytical methods that might uncover greater consistency between the studies. Moreover, both GDSC and CCLE have released new drug sensitivity and molecular profiling data, allowing us not only to revisit our initial analysis, but also to extend it using these new data.
To begin, we investigated alternative statistics to assess the inter-study consistency for drugs exhibiting different patterns of response across the collection of cell lines common to both studies. We then considered statistical methods for targeted drugs expected to be sensitive only in a subset of cell lines. We compared consistency estimates between continuous and discretized molecular features (gene expression, copy number variations and mutations) and drug sensitivity data, and importantly, assessed how potential discordance may affect the discovery of molecular features (biomarkers) predictive of drug response. We also revisited our analysis of consistency of molecular data between studies and evaluated "known biomarkers" of response expected to be predictive in these studies.
This extensive reanalysis found that by selecting specific statistical measures on a case-by-case basis, one can identify moderate to good consistency for two broad effect and three targeted therapies. However, overall, our results support our initial observations that drug sensitivity data in GDSC and CCLE are inconsistent for the majority of the drugs, even when considering metrics yielding the highest consistency for individual drugs. Our present analysis adds further evidence supporting the need for robust and standardized experimental pipelines to assure generation of comparable, biologically relevant measures of drug response as well as unbiased statistical and machine learning methods to better predict response. Failure to do so will continue to limit the potential for use of large-scale pharmacogenomic screens in reliable drug development and precision medicine applications.
Results
The overall analysis design of our study is represented in Figure 1 .
Intersection between GDSC and CCLE
To identify the largest set of cell lines and drugs profiled by both GDSC and CCLE, we used the PharmacoGx computational platform 11 that is able to store, analyze, and compare curated pharmacogenomic datasets. We created curated datasets for the new releases of the GDSC (July 2015) and CCLE (February 2015) projects. The improved curation of new data using PharmacoGx 11 identified 15 drugs in common between GDSC and CCLE as well 698 cell lines, originating from 23 tissue types (Figure 2 ). This is the same number of shared drugs but the updated datasets contains a larger number of common cell lines than the 471 reported in our previous analysis 7 .
Comparing single nucleotide polymorphism (SNP) fingerprints
To check the accuracy of cell line name matching, we compared single nucleotide polymorphism (SNP) fingerprints using data released in both studies. We first controlled for the quality of the SNP arrays and excluded 11 of 1,396 profiles due to low quality (see Methods). We then compared SNP fingerprints of cell lines with identical name using > 80% as threshold for concordance 12, 13 . Consistent with the results reported by the CCLE 2 , the vast majority of cell lines had highly concordant fingerprints (462 out of 470 cell lines with SNP profiles available in both GDSC and CCLE; Dataset 1). We found eight cell lines with same identifier but different SNP identity ( Figure 3 ); these were removed from our subsequent analyses to avoid discrepancies due to the use of possibly mislabeled or contaminated cell lines.
Estimation and filtering of drug dose-response curves We used the viability measures for each drug concentration in GDSC and CCLE to fit dose-response curves and assess their quality. An important factor influencing the fitting of drug doseresponse curves is the range of concentration used for each cell line/drug combination. In CCLE, all dose-response curves were measured at eight concentrations: 2.5×10 , 8×10 -1 , 2.5, and 8 μM. However, in GDSC response was measured at a different set of concentrations for each drug. The minimum concentrations for different drugs range from 3.125×10 -5 to 15.625 μM. In each case, the concentrations tested by GDSC form a geometric sequence of nine terms with a common ratio of two between successive concentrations. Thus, the maximum concentration tested for each drug is 256 times the minimum concentration for that drug and ranges from 8×10 -3 to 4000 μM.
To properly fit drug dose-response curves, one must make multiple assumptions regarding the cell viability measurements generated by the pharmacological platform used in a given study. For instance, one assumes that viability ranges between 0% and 100% after data normalization and that consecutive viability measurements remain stable or decrease monotonically reflecting response to the drug being tested. Quality controls were implemented to flag dose-response curves that strongly violate these assumptions (Supplementary Methods). We identified 2315 (2.9%) and 123 (1%) dose-response curves that failed to pass in GDSC and CCLE, respectively, as depicted in Figure 4 (all noisy curves are provided in Supplementary File 1. We excluded these cases to avoid erroneous curve fitting.
We used least squares optimization to fit a three-parameter sigmoid model (Methods) for the drug dose-response curves in GDSC and CCLE (Supplementary File 2). For each fitted curve, we computed the most widely used drug activity metrics, that are the area under the curve (AUC) and the drug concentration required to inhibit 50% of cell viability (IC 50 ).
Consistency of drug sensitivity data
We began by computing the area between the two drug doseresponse curves (ABC) to assess consistency of cell viability data for each cell line combination screened in both GDSC and CCLE using the common concentration range. ABC measures the difference between two drug-dose response curves by estimating the absolute area between these curves, which ranges from 0% (perfect consistency) to 100% (perfect inconsistency). The ABC statistic identified highly consistent ( Figure 5A , B) and highly inconsistent ( Figure 5C , D) dose-response curves between GDSC and CCLE. The mean of the ABC estimates for all drug-cell line combinations was 10% (Supplementary Figure 1A) , with paclitaxel yielding the highest discrepancies (Supplementary Figure 1B) .
We compared biological replicates in GDSC, which were performed independently at the Massachusetts General Hospital (MGH) and the Wellcome Trust Sanger Institute (WTSI). These experiments are comprised of 577 cell lines treated with AZD6482, a PI3Kβ inhibitor screened in GDSC (Supplementary File 3) . We computed the ABC of these biological replicates and observed both highly consistent and inconsistent cases (Supplementary Figure 2) . We then computed the median ABC values for each pair of drugs in GDSC and used these as a distance metric for complete linkage hierarchical clustering. We found that the MGH-and WTSI-administered AZD6482 experiments clustered together, suggesting that the differences between dose-response curves of biological replicates were smaller than the differences observed between different drugs (Supplementary Figure 3A) . We performed the same clustering analysis by computing the ABC-based distance between all the drugs in GDSC and CCLE and observed that only three out of the 15 common drugs clustered tightly (17-AAG, lapatinib, and PHA−665752; Supplementary Figure 3B ). Despite the small number of cell lines exhibiting sensitivity to PHA−665752 and lapatinib, these drugs closely clustered between GDSC and CCLE; however this was not the case for other targeted therapies, such as AZD0530, nilotinib, crizotinib and TAE684 Supplementary Figure 3B ).
Although the ABC values provide a measure of the degree of consistency between studies, it is the AUC and IC 50 estimates, and their correlation with molecular features (such as mutational status and gene expression) that are commonly used to assess drug response.
Therefore we revisited our comparative analysis of the drug sensitivity data using the expanded data and the standardized methods implemented in our PharmacoGx platform. Using the same three-parameter sigmoid model to fit drug dose-response curves in GDSC and CCLE (see Methods), we recomputed AUC and IC 50 values and observed very high correlation between published and recomputed drug sensitivity values for each study individually (Spearman > 0.93; Figure 6 ; Dataset 2).
It has been suggested that some of the observed inconsistencies between the GDSC and CCLE may be due to the nature of targeted therapies, which are expected to have selective activity against some cell lines 10, 14, 15 . This is a reasonable assumption as the measured response in insensitive cell lines may represent random technical noise that one should not expect to be correlated between experiments. We therefore decided to clearly discriminate between targeted drugs with narrow growth inhibition effects and drugs with broader effects. We used the full GDSC and CCLE datasets to compare the variation of the drug sensitivity data of known targeted and cytotoxic therapies as classified in the original studies (Supplementary Figure 4) . We observed that drugs can be classified in these two categories based on median absolute deviation (MAD) of the estimated AUC values (Youden's optimal cutoff 16 of AUC MAD > 0.13 for cytotoxic drugs). We then used this cutoff on the common drug-cell line combinations in GDSC and CCLE to define three classes of drugs (Supplementary Figure 5 ):
• No/little effect: Drugs with minimal observed activity (typically active in less than five sensitive cell lines with AUC > 0.2 or IC 50 < 1 μM in either study). This class includes sorafenib, erlotinib and PHA−665752.
• Narrow effect: Targeted drugs with activity observed for only a small subset of cell lines (AUC MAD ≤ 0.13). This group includes nilotinib, lapatinib, nutlin-3, PLX4720, crizotinib, PD-0332991, AZD0530, and TAE684.
• Broad effect: Drugs producing a response in a large number of cell lines (AUC MAD > 0.13). This includes AZD6244, PD-0325901, 17-AAG and paclitaxel.
We then compared the AUC ( Figure 9 ) values and calculated the consistency of drug sensitivity data between studies using all common cases and only those that the data suggested were sensitive in at least one study ( Figure 8 and Supplementary Figure 10 for AUC and IC 50 , respectively, and Dataset 3). Given that no single metric can capture all forms of consistency, we extended our previous study by using the Pearson correlation 17 , Spearman
18
, and Somers' Dxy 19 rank correlation coefficients to quantify the consistency of continuous drug sensitivity measurements across studies (see Methods).
As expected, no consistency was observed for drugs with "no effect" ( Figure 8A ). For AUC of drugs with narrow and broad effects, Somers' Dxy was the most stringent, with consistency estimated to be < 0.4 except for two drugs (PD-0325901 and 17-AAG), which were also the two drugs identified as the most consistent using Spearman correlation (ρ ~ 0.6; Figure 8A ). However, these statistics did not capture potential consistency for the most targeted therapies, nilotinib, crizotinib, and PLX4720, for which the Pearson correlation coefficient gave the best evidence of concordance, as this statistics is strongly influenced by a small number of highly sensitive cell lines (Figure 7) . Our results concur with the We then restricted our analysis to the cell lines identified as sensitive in at least one study and computed the same consistency measures ( Figure 8B ). To our surprise, eliminating the insensitive cell lines resulted in decreased consistency for most drugs, which suggests a high level of inconsistency across sensitive cell lines, with the only exceptions of the targeted drugs nilotinib and crizotinib.
To test whether discretization of drug sensitivity data into binary calls ("insensitive" vs. "sensitive"; see Methods) improves consistency across studies, we used three association statistics, the Matthews correlation coefficient 20 , Cramer's V
21
, and the informedness 22 statistics ( Figure 8C ). These statistics are designed for use with imbalanced classes, which is particularly relevant in large pharmacogenomic datasets where, for targeted therapies, there are often many more insensitive cell lines than sensitive ones. As expected, some of the targeted therapies, nilotinib and PLX4720 (and nutlin-3 using informedness), yielded high level of consistency, but this was not the case for the other targeted therapies. We also found that the drug sensitivity calls for drugs with broader inhibitory effects were also poorly correlated between studies ( Figure 8C ).
We performed the same analysis using IC 50 values truncated to the maximum concentration used for each drug in each study separately.
We observed similar patterns with nilotinib and crizotinib yielding moderate to high consistency across studies (Supplementary Figure 10) . Note that Somers' Dxy rank correlation is biased in the presence of many repeated values in the datasets being analyzed, which is the case for truncated IC 50 -pairs of cell line with identical IC 50 values in one dataset but not in the other will not be taken into account as evidence of inconsistency -which explains the artifactual perfect consistency it suggests for both nilotinib and crizotinib. 
Consistency of molecular profiles across cell lines
Discovering new biomarkers predictive of drug response requires both robust pharmacological data and molecular profiles. In our original study, we showed that the gene expression profiles for each cell line profiled by both GDSC and CCLE were highly consistent. However, we found that mutation profiles were only moderately consistent, a result that was later confirmed by Hudson et al. 23 .
There have been questions as to whether the measures of consistency we reported for drug response should be compared to those we reported for gene expression. Specifically, we reported correlations based on comparing drug response "across cell lines," meaning that we examined the correlation of response of each cell line to a particular drug reported by the GDSC with the response of the same cell line to the same drug reported by the CCLE. In contrast we reported correlation of gene expression levels "between cell lines," meaning that we compared the expression of all genes within each cell line in the GDSC to the expression of all genes in the same cell line in the CCLE (see Supplementary Methods). It has been suggested that a more valid comparison would be to compare both drug response and gene expression across cell lines. We report the results of such an "across cell lines" analysis of gene expression here, computed using techniques analogous to those we used to compare drug response.
We began by comparing the distribution of gene expression measurements generated using the microarray Affymetrix HG-U219 platform in GDSC, the microarray Affymetrix HG-U133PLUS2 platform and the new Illumina RNA-seq data in CCLE (Supplementary Figure 11) . We observed similar bimodal distributions, suggesting the presence of a natural cutoff to discriminate between lowly vs. highly expressed genes. We therefore fit a mixture of two gaussians and identified an expression cutoff for each platform separately (Supplementary Figure 11) . We then compared the consistency of continuous and discretized gene expression values between (i) the microarray Affymetrix HG-U133PLUS2 and Illumina RNA-seq platforms within CCLE (intra-lab consistency); (ii) the microarray Affymetrix HG-U219 and HG-U133PLUS2 platforms used in GDSC and CCLE, respectively (microarray, inter-lab consistency); and (iii) the microarray Affymetrix HG-U219 and Illumina RNA-seq platforms used in GDSC and CCLE, respectively (inter-lab consistency). We performed a similar analysis for CNV log-ratios and observed high consistency across cell lines ( Figure 9A ). Supporting our previous observations, we found that CNV and gene expression measurements are significantly more consistent than drug sensitivity values when using all cell lines (Wilcoxon rank sum test p-value < 0.05; Figure 9A ; Supplementary Figure 12A) .
Similarly to the filtering we performed for drug sensitivity data, we subsequently restricted our analysis to the cell lines showing high expression of a given gene/cell line combination in at least one study. Again, CNV and gene expression measurements were significantly more consistent than drug sensitivity values in this case (Wilcoxon rank sum test p-value < 0.05; Figure 9B ; Supplementary Figure 12B ). When dichotomizing data into lowly/highly expressing, amplifications/deletions, and wild type/mutated cell lines and insensitive/sensitive cell lines, the CNV and gene expression data were still more consistent ( Figure 9C ) although the difference was not always significant (Supplementary Figure 12C) . Concurring with the report of Hudson et al.
23
, we observed low consistency for mutation calls across cell lines ( Figure 9C ).
Consistency of gene-drug associations
The primary goal of the GDSC and CCLE studies was to identify new genomic predictors of drug response for both targeted and cytotoxic therapies. We therefore evaluated whether the good consistency in drug sensitivity data observed for nilotinib, PLX4720 and crizotinib, and the moderate consistency observed for 17-AAG and PD-0332901 would translate in reproducible biomarkers. We estimated gene-drug associations by fitting, for each gene and drug, a linear regression model including gene expression, CNV and mutations as predictors of drug sensitivity, adjusted for tissue source (see Methods). As illustrated in Figure 1 , we used the molecular and pharmacological data generated independently in GDSC and CCLE to identify and compare gene-drug associations. This approach prevents any information leak between the two datasets, which may lead to overoptimistic consistency between the studies, as in the recent comparative study published by the GDSC and CCLE investigators 9 . Given the high correlation between the published and recomputed AUC values in each study ( Figure 6 ) and their similar consistency (Figure 9 ), all gene-drug associations were computed using published AUC for clarity.
We first computed the strength and significance of each gene in both datasets separately. Similarly to our initial study 7 , the strength of a given gene-drug association is provided by the standardized coefficient associated to the corresponding gene profile in the linear model and its significance is provided by the p-value of this coefficient (see Methods). We then identified gene-drug associations that were reproducible in both datasets (same sign and False Discovery Rate [FDR] < 5%) or that were dataset-specific (different sign or significant in only one dataset) using continuous (Supplementary Figure 13 We assessed the overlap of gene-drug associations discovered in both datasets using the Jaccard index 24 . All Jaccard indices were low, with nilotinib yielded the largest overlap of gene-drug associations (32%), followed by PD-0325901 and erlotinib (almost 20%), while the other drugs yielded less than 15% overlap (Supplementary Figure 17) . Our results further indicate that larger overlap exists for gene-drug associations identified using the continuous drug sensitivity data compared with associations using discretized drug sensitivity calls (Wilcoxon signed rank test p-value of 4×10 -2 and 2×10 -3 for the common set and the full set of cell lines, respectively). We therefore focused our analyses on the gene-drug associations Figure 9 . Consistency of molecular profiles (gene expression, copy number variation and mutation) and drug sensitivity data between GDSC and CCLE using multiple consistency measures. (A) Consistency assessed using the full set of cancer cell lines screened in both studies. (B) Consistency assessed using only sensitive cell lines (AUC >0.2 / IC 50 <1 µM and AUC >0.4 / IC 50 <10 µM for targeted and cytotoxic drugs, respectively). (C) Consistently assessed by discretizing the molecular and drug sensitivity data. GE.CCLE. ARRAY.RNASEQ: Consistency between gene expression data generated using Affymetrix HG-U133PLUS2 microarray and Illumina RNA-seq platforms within CCLE; GE.ARRAYS: Consistency between gene expression data generated using Affymetrix HG-U133A and HG-U133PLUS2 microarray platforms in GDSC and CCLE, respectively; GE.ARRAY.RNASEQ: Consistency between gene expression data generated using Affymetrix HG-U133A microarray and Illumina RNA-seq platforms in GDSC and CCLE, respectively; CNV: Consistency of copy number variation data in CCLE and GDSC, respectively; MUTATION: Consistency of mutation profiles in CCLE and GDSC, respectively. PCC: Pearson correlation coefficient; SCC: Spearman rank-based correlation coefficient; DXY: Somers' Dxy rank correlation; MCC: Matthews correlation coefficient; CRAMERV: Cramer's V statistic; INFORM: Informedness. identified using continuous published AUC values. The number (and identity) of gene-drug associations computed using continuous published AUC values are provided in Supplementary Table 1  and Supplementary Table 2 (Dataset 5 and Dataset 6) for common and all cell lines, respectively.
Given that simply intersecting significant gene-drug associations identified in each dataset separately yielded poor reproducibility for all drugs, we sought to more closely mimic the biomarker discovery and validation process. We therefore used one dataset to discover significant gene-drug associations and test whether this subset of markers validated in an independent dataset. Using the discovery dataset, gene-drug associations are first ranked by nominal p-values and their FDR is computed. An association is selected if it is part of the top 100 markers and its FDR is less than 5%. This procedure ensure to control for both significance and number of selected biomarkers, which can vary with respect to the cell line panel used for the analysis (larger panels enable the identification of more significant biomarkers due to increased statistical power). A genedrug association is validated in an independent dataset if its nominal p-value is less than 0.05 and its "direction", that is whether the marker is associated with sensitivity or resistance, is identical to the one estimated during the discovery process.
We computed the proportions of validated gene-drug associations for each drug using all available genomic molecular data profiles in GDSC as discovery set and CCLE as validation set, and vice versa ( Figure 10 ). Overall, we found that biomarkers for PD-0325901, PLX4720 and nilotinib yielded a high validation rate (> 80%) with either dataset as discovery set using the common cell lines screened in GDSC and CCLE ( Figure 10A ). When using the entire cell line panels used in each study, two more drugs --lapatinib and erlotinib --yielded high validation rate ( Figure 10B ). 17-AAG, and TAE684 yielded validation rate between 60% and 80%, while the other drugs yielded a validation rate around 50% or lower. For ten out of the fifteen drugs, using the entire panel of cell lines screened in each study ( Figure 10B ) improved the validation rate compared to limiting the analysis to common cell lines ( Figure 10A ). However, validation rate decreased for three drugs, suggesting that using large, but different panels of cell lines may increase statistical power but could also introduce biases in the biomarker discovery process.
We then investigated whether higher validation rates would be obtained by using more stringent significance threshold and relaxing the constraint on the number of significant associations in the discovery set (Supplementary Figure 18 and Supplementary Figure 19 ). Using common cell lines, we found that proportion of validated gene-drug association monotonically increases with FDR stringency for six drugs, with very high validation rate for the most stringent FDR cutoff (validation rate > 80% for FDR < 0.1%) for 17-AAG, PD-0325901, PLX4720 and nilotinib using either dataset as discovery set (Supplementary Figure 18) . Using the entire panel of cell lines in each study actually improved validation rate for six drugs, AZD6244, TAE684, AZD0530, lapatinib -and erlotinib and sorafenib, for which insufficient number of sensitive cell lines were screened in both GDSC and CCLE (Supplementary Figure 19) . However, validation rate decreased for 17-AAG, crizotinib and PLX4720, which suggests again that large, but different panels of cell lines might introduce selection bias for some drugs.
Known biomarkers
As reported in the original GDSC (1) and CCLE (2) publications and in recent reports 10,14,15 , several known biomarkers for targeted therapies have been shown to be predictive in both GDSC and CCLE. In our initial comparative study we also found the following known gene-drug associations:
• BRAF mutations were significantly associated with sensitivity to MEK inhibitors (AZD6244 and PD-0325901) and BRAF V600E inhibitor (PLX4720) with nominal p-values < 0.01; see Supplementary File 10-Supplementary File 13 of our initial study.
• ERBB2 expression was significantly associated with sensitivity to lapatinib with nominal p-value = 0.04 and 8.4×10 -15 for GDSC and CCLE, respectively; see Supplementary File 4 and Supplementary File 5 of our initial study.
• NQ01 expression was significantly associated with sensitivity to 17-AAG with nominal p-value = 2.4×10 -13
and 6.2×10 -14 for GDSC and CCLE, respectively; see Supplementary File 4 and Supplementary File 5 of our initial study.
• MDM2 expression was significantly associated with sensitivity to Nutlin-3 with nominal p-value = 7.7×10
-18
and 7×10 -8 for GDSC and CCLE, respectively; see Supplementary File 4 and Supplementary File 5 of our initial study.
• ALK expression was significantly associated with sensitivity to TAE684 with nominal p-value = 1.6×10 -9 and 1.7×10 -9 or GDSC and CCLE, respectively; see Supplementary File 4 and Supplementary File 5 of our initial study.
We revisited our biomarker analysis using the new data released by GDSC and CCLE to test whether additional known biomarkers can be identified. We recomputed all gene-drug associations based on expression, mutation, gene-fusion and amplification data using the common cell lines between studies Dataset 5, and entire panel of cell lines in each study (Dataset 6). We confirmed the reproducibility of the known associations reported in our initial study, but we were not able to find reproducible associations for EGFR mutations with response to AZD0530 and erlotinib, and HGF expression with response to crizotinib ( Table 1 ). The reproducibility of the majority of these previously known associations attests to the relevance of the GDSC and CCLE datasets although our results demonstrated that the noise and inconsistency in drug sensitivity data render discovery of new biomarkers difficult for the majority of the drugs. . Proportion of gene-drug associations identified in a discovery set (top 100 gene-drug associations as ranked by p-values and FDR < 5%) and validated in an independent validation dataset. In blue and red are the gene-drug associations identified in GDSC and CCLE, respectively. Associations are identified using molecular profiles including gene expression, mutation and copy number variation data as input and (A) continuous published AUC values as output in a linear model using only common cell lines or (B) all cell lines. The number of selected gene-drugs associations in each datasets is provided in parentheses. The symbol '*' represents the significance of the proportion of validated gene-drug associations, computed as the frequency of 1000 random subsets of markers of the same size having equal or greater validation rate compared to the observed rate. 
Discussion
Our original motivation in analyzing the GDSC and CCLE data was to discover predictive genomic biomarkers of drug response. When we applied a number of methods using one study to select genomic features and to train a classifier, and then applied it to predict reported drug response in the second study, our predictive models failed to validate for half of the drugs tested 3
. Indeed, out of nine predictors yielding concordance index 25 ≥0.65 in cross-validation in the training set (GDSC), only four were validated in identical cell lines treated with the same drugs in the validation set (CCLE) 3 .
As we explored the reasons for this failure, we first checked whether cell lines could have drifted and consequently exhibited different transcriptional profiles between GDSC and CCLE. We found that any genome-wide molecular profile in one study would almost always identify "itself" (its purported biological replica) as being most similar among the cell lines in the other study. In a way this is not surprising. When gene expression studies were in their infancy, there were many reports that compared the results from studies and found that they were inconsistent and unreproducible in new studies -as demonstrated by the countless microarray signatures that fail to reproduce beyond their initial publication. As a result, scientists involved in gene expression studies "circled the wagons" and developed both much more standardized laboratory protocols and "best practices" for reproducible analysis, including data normalization and batch corrections, that now mean that independent measurements from different laboratories are far more often consistent and so can be used for signature development and validation 26, 27 .
Unexpectedly, when we compared phenotypic measures of drug response that were released by the GDSC and CCLE projects, we found discrepancies in growth inhibition effects of multiple anticancer agents. What that means in practice is that, for some drugs, a molecular biomarker of drug response learned from one study would not likely be predictive of the reported response in the other. And consequently, neither of the studies might be useful in predicting response in patients as many had hoped when these large pharmacogenomic screens were published.
The feedback from the scientific community on our analysis, the availability of new data from the GDSC and CCLE, as well as improvements in the PharmacoGx software platform we developed to support this type of analyses 11 , prompted us to revisit the question of consistency in these studies to see if we could find a principled way to identify correlated drug response phenotypes. By testing a variety of methods of classifying the data, and choosing the metric which gave the best consistency for each drug, we were able to find moderate to good consistency of sensitivity data for two broad effect and three targeted drugs. We also confirmed the overall lack of consistency between the studies for eight drugs, while there were not enough sensitive cell lines that had been screened by both GDSC and CCLE to properly assess consistency for the remaining three drugs. The summary box included with this paper briefly describes the most significant issues that people have raised in discussing our previous findings with us and summarizes what we have found in our reanalysis.
Some have suggested that one way to improve correlation would have been to compare the studies and throw out the most discordant data as noise and then compare the remaining concordant data. While this would certainly find concordance in the remaining data, the approach is equivalent to fitting data to a desired result, which is bad practice and certainly could not be extended to other data sets or to the classification of patient tumors as responsive or nonresponsive to a particular therapy. There is, however, merit in the suggestion that one would not expect to see correlation in noise. And noise is precisely what one would expect to see in drug response data from cell lines that are resistant to a particular drug or nonresponsive across the range of doses tested. As reported here, filtering the data in each study independently to classify cell lines in a binary fashion, and then comparing the binary classification between studies using a variety of metrics developed to handle the intricacies of this sort of response data, also failed to find simple correlations in the data, except for three of the targeted therapies, nilotinib, PLX4720 and crizotinib. What this ultimately means is that the most and the least sensitive cell lines would not appear to be the same when comparing the two studies.
There are many reasons for potential differences in measured phenotypes reported by the GDSC and CCLE, including substantial differences in doses used for each drug and in the methods used to both assay cell viability and to estimate drug response parameters. By comparing GDSC and CCLE with an independent pharmacogenomic dataset published by GlaxoSmithKline (GSK), we showed that higher consistency is achieved when the same pharmacological assay is used (GSK and CCLE used the CellTiter-Glo assay, while GDSC used Syto60) 7, 8 . Genentech also used the CellTiter-Glo assay and observed higher consistency of drug sensitivity data with CCLE compared to GDSC 10 . The authors elegantly evaluated the impact of cell viability readout, growth medium, and seeding density. They observed only weak impact of the choice of pharmacological assay as their follow-up screen with the Syto60 assay clustered closer to their own CellTiter-Glo screen than GDSC, suggesting that other parameters might have driven the inconsistency observed with GDSC 10 . They further showed that increased fetal bovine serum and seeding cell density had a systematic effect on mean cell viability. Pozdeyev et al. showed that restricting the computation of AUC to the concentration range shared between GDSC and CCLE, the equivalent of our AUC* drug sensitivity measure, yielded a small, but statistically significant improvement in consistent of pharmacological profiles 28 . Ultimately what our analysis and these recent reports suggest is that not only drug sensitivity measurements must be carefully and appropriately compared, but also that there is a pressing need for more robust pharmacological assays and standardized computational methods for modeling drug response. However, in the absence of a "gold standard" screening platform demonstrated to accurately recapitulate drug response in vivo, the use of multiple assays is critical to probe different biological aspects of growth inhibition. Given that GDSC and CCLE used different pharmacological assays, it makes the release of these pharmacogenomic data even more valuable.
The primary goal of the GDSC and CCLE studies was to link molecular features of a large panel of cancer cell lines to their sensitivity to cytotoxic and targeted drugs. The reproducibility of most of the known gene-drug associations provides evidence that these large pharmacogenomic datasets are biologically relevant. When we investigated whether we could find significant gene-drug associations discovered in one dataset that validate in the other independent dataset, we observed over 75% validation rate for the most significant molecular biomarkers for eight of 15 drugs, which is a major improvement over our initial comparative study. However, this does not suggest that one can use these studies to find new, reproducible gene-drug associations for the rest of the drugs, as the majority of associations can be found in only one dataset but not in both. However, GDSC and CCLE could be jointly analyzed to identify biomarkers that are robust to the use of different biological assays, and are therefore more likely to work in new biological contexts 29 .
This study has several potential limitations. First, while the raw drug sensitivity data are publicly available for GDSC, these data have not been released within the CCLE study. We could not fit the drug dose-response curves using the technical triplicates but rather relied on the published median sensitivity values. The lack of technical replicates in CCLE also prevented us to assess the level of noise of the drug sensitivity measurements. Second, we discretized drug sensitivity values by selecting a common threshold to discriminate between insensitive (AUC ≤ 0.2 and IC 50 ≥ 1 μM) and the rest of the cell lines for all the targeted agents. However, it is clear that such a threshold could be optimized for each drug, which might have an impact on the consistency of drug phenotypes and gene-drug associations based on binary sensitivity calls, as was done in breast cancer 30 and in our response to the critic of Geeleher et al. 31, 32 . Lastly, the current set of mutations assessed in both study is small (64 mutations), which drastically limits the search for mutation-based and other genomic aberrations associated with drug response. The exome-sequencing data available within the new GDSC1000 dataset will enable to better explore the genomic space of biomarkers in cancer cell lines, and their reproducibility across studies.
Conclusion
As is true of many scientists working in genomics and oncology, we were excited when the GDSC and CCLE released their initial data sets and were hopeful that these projects would help to accelerate drug discovery and further the development of precision medicine in oncology. However, what we found initially, and what the reanalysis presented here further indicates, is that there are inconsistencies between the measured phenotypic response to drugs in these studies. Even in our reanalysis, where we used methods specific to individual drugs and the response characteristics of the cell lines tested, we were only able to find new biomarkers consistently predictive of response for around half of the drugs screened in both studies. Consequently, it is challenging to use the data from these studies to develop general purpose classification rules for all drugs.
Our finding that molecular profiles are significantly more consistent than drug sensitivity data, indicates that the main barrier to biomarker development using these data is the discrepancy in the reported response phenotypes for many drugs. The experimental protocols and pharmacological assays used in the GDSC and CCLE studies are the state-of-the-art for high-throughput drug screening projects. Even though technical and biological replicates are necessary to assess and account for noise in drug sensitivity measurements, it is clear that the assays used in GDSC and CCLE probe different aspects of the biology underlying drug-induced growth inhibition. Without knowing which assay is more relevant for in vivo drug response, more research will be required to best leverage these complementary assays for robust biomarker discovery.
From having worked in large-scale genomic analyses, we recognize the challenges involved in planning and executing such studies and commend the GDSC and CCLE for their work and for making all the data available. However, we strongly encourage the GDSC, the CCLE, the pharmacogenomics and bioinformatics communities as a whole, to invest the necessary time and effort to account for the noise in drug response measurements and the complementary nature of different assays in order to assure that these studies are relevant for predicting response in patients. The recent report from Genentech is a significant step in this direction. Ultimately, that effort will help to assure that mammoth undertakings in drug characterization can deliver on their promise to identify better therapies and biomarkers predictive of response.
Methods

The PharmacoGx platform
The lack of standardization of cell line and drug identifiers hinders comparison of molecular and pharmacological data between largescale pharmacogenomic studies, such as the GDSC and CCLE. To address this issue we developed PharmacoGx, a computational platform enabling users to download and interrogate large pharmacogenomic datasets that were extensively curated to ensure maximum overlap and consistency
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. PharmacoGx provides (i) a new object class, called PharmacoSet, that acts as a container for the high-throughput pharmacological and molecular data generated in large pharmacogenomics studies (detailed structure provided in Supplementary Methods); and (ii) a set of parallelized functions to assess the reproducibility of pharmacological and molecular data and to identify molecular features associated with drug effects. The PharmacoGx package is open-source and publicly available on Bioconductor.
The GDSC (formerly CGP) dataset Drug sensitivity data. We used the data release 5 (June 2014) with 6,734 new IC 50 values for a total of 79,903 drug dose-response curves for 139 different drugs tested on a panel of up to 672 unique cell lines. The data are accessible from ftp://ftp.sanger. ac.uk/pub4/cancerrxgene/releases/release-5.0/.
Molecular profiles.
Gene expression data were downloaded from ArrayExpress, accession number E-MTAB-3610. These new data were generated using Affymetrix HG-U219 microarray platform. We processed and normalized the CEL files using RMA 33 with BrainArray 34 chip description file based on Ensembl gene identifiers (version 19). This resulted in a matrix of normalized expression for 17,616 unique Ensembl gene ids. SNP array data for the Genome-Wide Human SNP Array 6.0 platform were downloaded from GEO with the accession number GSE36139. We processed the raw CEL data using Affymetrix Power Tools (APT) v1.16.1. Copy number segments were generated using HAPSEG v1.1.1 35 based on RMA-normalized signal intensities and Birdseed v2-called genotypes. These segments were further refined using ABSOLUTE v1.0.6 36 to identify allele-specificity within each segment. Mutation and gene fusion calls were downloaded from the GDSC website and processed as in our initial study 7 .
The CCLE dataset Drug sensitivity data. We used the drug sensitivity data available from the CCLE website (https://portals.broadinstitute.org/ccle/ data/browseData) and updated on February 2015 with a total number of 11,670 dose-response curves for 24 drugs tested in a panel of up to 504 cell lines.
Gene expression data were downloaded from the CCLE website and CGHub 37 for the Affymetrix HG-U133PLUS2 and Illumina HiSeq 2500 platforms, respectively. SNP array data were downloaded from EMBL-EBI with the accession number EGAD00010000644. Normalization of microarray data (1036 cell lines) and SNP array data (1190 cell lines) was performed the same way than for GDSC. RNA-seq data (935 cell lines) were downloaded as BAM files previously aligned using TopHat 38 and the quantification of gene expression was performed using Cufflinks 38 based on Ensembl GrCh37 human reference genome. Mutation data were retrieved from the CCLE website and processed as in our initial study 7 .
Curation of drug and cell line identifiers The lack of standardization for cell line names and drug identifiers represents a major barrier for performing comparative analyses of large pharmacogenomics studies, such as GDSC and CCLE. We therefore curated these datasets to maximize the overlap in cell lines and drugs by assigning a unique identifier to each cell line and drug. Entities with the same unique identifier were matched. Manual search was then applied to match any remaining cell lines or drugs which were not matched based on string similarity; annotations were consistently extracted from Cellosaurus 39 . The cell line curation was validated by ensuring that the cell lines with matched name had a similar SNP fingerprint (see below). The drug curation was validated by examining the extended fingerprint of each of their SMILES strings 40 and ensuring that the Tanimoto similarity 41 between two drugs called as the same, as determined by this fingerprint, was above 0.95.
Cell line identity using SNP fingerprinting
To assess the identity of cell lines from GDSC and CCLE, data of low quality were first excluded from our analysis panel (detailed procedure described in Supplementary Methods). Of the 973 CEL files from GDSC, only 66 fell below the 0.4 threshold (6.88%) for contrast QC scores, indicating issues in resolving base calls. Additionally, five of the 1,190 CEL files from CCLE had an absolute difference between contrast QC scores for Nsp and Sty fragments greater than 2, thus indicating some issues with the efficacy of one enzyme set during sample preparation. CEL files with contrast QC scores indicative of some sort of issue with the assay that would affect the genotype call rate or birdseed accuracy were removed and genotype calling was conducted on the remaining CEL files using Birdseed version 2. The resulting files were then filtered to keep only the 1006 SNP fingerprints that originated from CEL files that had a common cell line annotation between GDSC and CCLE (503 CEL files from each). Finally, pairwise concordances of all SNP fingerprints were generated according to the method outlined by Hong et al.
.
Drug dose-response curves To identify artefactual drug dose-response curves due to experimental or normalization issues, we developed simple quality controls (QC; details in Supplementary Methods). Briefly, we checked whether normalized viability measurements range between 0% and 100% and that drug-response curve is monotically non-increasing as expected. The drug dose-response curves which did not pass these simple QC were flagged and removed from subsequent analyses as the curve fitting would have yielded erroneous results.
All dose-response curves were fitted to the equation
where y = 0 denotes death of all infected cells, y = y(0) = 1 denotes no effect of the drug dose, EC inf is the viability observed in the presence of an arbitrarily large concentration of drug, EC 50 is the concentration at which viability is reduced by half as much as it is in the presence of an arbitrarily large concentration of drug, and HS is a parameter describing the cooperativity of binding. HS < 1 denotes negative binding cooperativity, HS = 1 denotes noncooperative binding, and HS > 1 denotes positive binding cooperativity. The parameters of the curves were fitted using the least squares optimization framework. Comparison of our doseresponse curve model with those used in the GDSC and CCLE publications is provided in Supplementary Methods.
Discretization of pharmacogenomic data
Drug sensitivity data. To discretize the drug sensitivity data, we used AUC ≤ 0.2 (IC 50 ≥ 1 μM) and AUC ≤ 0.4 (IC 50 ≥ 10 μM) to identify the "insensitive" cell lines for targeted and cytotoxic drugs, respectively, while the rest of the cell lines are classified as "sensitive". These reasonable, although somewhat arbitrary, cutoffs enabled to explore the potential of such binary drug sensitivity calls as new drug phenotypic measures to find consistency in drug sensitivity data and gene-drug associations.
Gene expression data. To discretize the drug sensitivity data into lowly vs. highly expressed genes, we fit a mixture of two Gaussians of unequal variance using the full distribution of expression values of the 17,401 genes in common between GDSC and CCLE datasets. We defined the expression threshold as the expression value for which the posterior probability of belonging to the left tail of the highly expression distribution is 10%.
Mutation data.
Similarly to the GDSC and CCLE publications, we transformed the original mutation data into binary values that represent the absence (0) or presence (1) of any missense mutations in a given gene in a given cell line.
Gene-drug associations
We assessed the association, across cell lines, between a molecular feature and response to a given drug, referred to as gene-drug association, using a linear regression model adjusted for tissue source:
where Y denotes the drug sensitivity variable, G i and T denote the expression of gene i and the tissue source respectively, and βs are the regression coefficients. As we recognized that continuous drug sensitivity is not normally distributed, which violates one of the assumption of the linear regression model described above, we also assessed the consistency of gene-drug association using discretized (binary) drug sensitivity calls as the response variable in a logistic regression model adjusted for tissue source, similarly to the linear regression model.
Measure of consistency
Area between curves (ABC). To quantify the difference between two dose-response curves, we computed the area between curves (ABC). ABC is calculated by taking the unsigned area between the two curves over the intersection of the concentration range tested in the two experiments of interest, and normalizing that area by the length of the intersection interval. In the present study, we compared the curves fitted for the same drug-cell line combinations tested both in GDSC and CCLE. Further details are provided in Supplementary Methods.
Pearson correlation coefficient (PCC).
PCC is a measure of the linear correlation between two variables, giving a value between +1 and −1 inclusive, where 1 represents total positive correlation, 0 represents no correlation, and −1 represents total negative correlation 17 . PCC is sensitive to the presence of outliers, like a few sensitive cell lines in the case of drug sensitivity data measured for targeted therapies or genes rarely expressed.
Spearman rank correlation coefficient (SCC)
. SCC is a nonparametric measure of statistical dependence between two variables and is defined as the Pearson correlation coefficient between the ranked variables 18 . It assesses how well the relationship between two variables can be described using a monotonic function. If there are no repeated data values, a perfect Spearman correlation of +1 or −1 occurs when each of the variables is a perfect monotone function of the other. Contrary to PCC, SCC can capture non linear relationship between variables but is insensitive to outliers, which is frequent for drug sensitivity data measured for targeted therapies or genes rarely expressed.
Somers' Dxy rank correlation (DXY)
. DXY is a non-parametric measure of association equivalent to (C -0.5) * 2 where C represents the concordance index 25 that is the probability that two variables will rank a random pair of samples the same way 19 .
Matthews correlation coefficient (MCC). MCC
20 is used in machine learning as a measure of the quality of classification predictions. It takes into account true and false positives and negatives, acting as a balanced measure which can be used when the classes are of different sizes. MCC is in essence a correlation coefficient between two binary classifications; it returns a value between −1 (perfect opposite classification) and +1 (identical classifications), with 0 representing association no better than random chance.
Cramer's V (CRAMERV).
CRAMERV is a measure of association between two nominal variables, based on Pearson's chi-squared statistic, giving a value between 0 (no association) and +1 (perfect association) 21 . In the case of 2×2 contingency table, such as binary drug sensitivity or gene expression measurements, CRAMERV is equivalent to the Phi coefficient.
Informedness (INFORM).
For a 2×2 contingency table comparing two binary classifications, INFORM can be defined as Specificity + Sensitivity -1, which is equivalent to true positive rate -false positive rate 22 . The magnitude of INFORM gives the probability of an informed decision between the two classes, where INFORM > 0 represents appropriate use of information, 0 represents chance-level decision, < 0 represents perverse use of information.
Data and software availability
Open Science Framework: Dataset: Revisiting inconsistency in large pharmacogenomics studies, doi 10.17605/osf.io/xxxx 43 Data: The list of all the pharmacogenomic datasets available through the PharmacoGx platform can be obtained from R using the availablePSets() function from the R/Bioconductor library PharmacoGx.
The GDSC and CCLE PharmacoSets used in this study are available from pmgenomics.ca/bhklab/sites/default/files/downloads/ using the downloadPset() function.
Code: The R code necessary to replicate all the results presented in this article is available from the cdrug2 GitHub repository. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
"Our finding that molecular profiles are significantly more consistent than drug sensitivity data, indicates that the main barrier to biomarker development using these data is the unreliability in the reported response phenotypes for many drugs. For studies such as these to realize their full potential, additional work must be done to develop robust and reproducible experimental and analytical protocols so that the same compound, tested on the same set of cell lines by different groups, yields consistent and comparable results. Barring this, a predictive biomarker of response developed from one study is unlikely to be able to reliably validated on another, and consequently, is unlikely to be useful in predicting patient response." Again, I think the concern here is wrong for the same reasons I describe above. The main barrier is *not* the differences in quality between assays. The author's response to my initial concern shifts it to variability within an assay, but that is obvious --if an assay doesn't work it can't be informative. Bad assays should be excluded. Period. The original premise of the work was that differences in results between assays was problematic but that is not the problem. Its that specific assays do not produce the high quality data necessary.
My further points remain. I agree it may be hard, but it is possible.
No competing interests were disclosed.
Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Reader Comment 07 Aug 2017 ,
Benjamin Haibe-Kains
We have now updated the discussion and conclusion to reflect the fact that the noise within assays must be assessed and accounted for, and the complementarity across assays offer new opportunities to develop more robust biomarkers. Updated parts are underlined and in italic.
"Our finding that molecular profiles are significantly more consistent than drug sensitivity data, indicates that the main barrier to biomarker development using these data is the discrepancy in the reported response phenotypes for many drugs.
The experimental protocols and pharmacological assays used in the GDSC and CCLE studies are the state-of-the-art for high-throughput drug screening projects. Even though technical and biological replicates are necessary to assess and account for noise in drug sensitivity measurements, it is clear that the assays used in GDSC and CCLE probe different aspects of the biology underlying drug-induced growth inhibition. Without knowing which assay is more relevant for in vivo drug response, more research will be required to best leverage these complementary assays for robust biomarker discovery.
From having worked in large-scale genomic analyses, we recognize the challenges involved in planning and executing such studies and commend the GDSC and CCLE for their work and for making all the data available. However, we strongly encourage the GDSC, the CCLE, the pharmacogenomics and bioinformatics communities as a whole,
to invest the necessary time and effort to account for the noise in drug response measurements and the complementary nature of different assays in order to assure that these studies are relevant for predicting response in
The recent report from Genentech is a significant step in this direction. Ultimately, that patients. effort will help to assure that mammoth undertakings in drug characterization can deliver on their promise to identify better therapies and biomarkers predictive of response." promise to identify better therapies and biomarkers predictive of response."
We agree with the reviewer regarding the reviewer's comments on drug-specific cutoffs, and have updated the paragraph about the limitations of our study to reflect this important point. The authors address two highly important areas in basic and clinical research: data reproducibility and predictive (gene expression) biomarkers based on drug sensitivity data. The former issue represents a hallmark of basic science research; where results derived from different labs and measurement techniques serve to establish strong confidence in a proposed experimental protocol. The latter issue pertains best to highly confident (e.g. reproducible or consistent) experimental measurements; while data inconsistencies foreshadow a Pandora's Box of alternatives in the search for the origins of these differences.
None
With respect to the issue of data reproducibility, I find no fault in the new manuscript. All of the results reported in the original 2013 paper and current paper under review can be obtained from their Supplementary R code. With a bit of diligence and tenacity, sequentially stepping through their R-code will yield the reported figures and tables. Towards that end, the original R-code is tedious, but their addition of an open-source R-package, PharmacoGx, relieves much of the tedium. In fact, the authors must be applauded for making their analysis completely reproducible, a feat rarely achieved with biological results.
Notwithstanding, the results remain largely the same; inconsistencies remain in the drug sensitivity profiles between the GCSC[2] and CCLE [1] groups. Data analysis based on alternative methods appear to be constructed around the arguments proposed in the pair of Brief Communications Arising from the original paper [4, 5] . The general idea of this alternative data analysis is based on the limited role of weakly responsive tumor cells, and thus a failure to contribute to meaningful statistics. While segregating the data into three classes (drugs with no observed tumor cell activity, activity in a few tumor cells and activity in a large number of tumor cells) improves the statistics, the differences largely remain. large number of tumor cells) improves the statistics, the differences largely remain.
Speculations about the differences between the two datasets focus, naturally, on each measurement platform. The current manuscript's proposal of internal standardization may help identify the origin(s) of these differences, but this alone may not be sufficient. In this regard, I would recommend the Supplementary Information (all 47 pages) from the original article [3] . Specifically, Section 3, Comparison of experimental protocols, and the included Comparative table. The details of this section identify a number of platform differences that may underlie their measurement differences. Although not within the scope of the current article, a future study focused on these differences, combined with standardization, rather than looking for answers by segregating the data into three response classes, would be highly informative. An alternative speculation regarding data inconsistencies considers the 'dated' possibility that each tumor cell's drug sensitivity and underlying phenotypic architecture (expression, mutation, snp, etc.) exemplifies a 'snowflake' phenomenon. Each tumor cell represents a unique circumstance, which can be modulated by any sort of environmental condition. Thus a drug response, even for the same tumor cell, may exhibit variation. Under these circumstances, the functional pathways, represented by groups of genes and their concordant expressions, become the focus, and derivation of pathway-based scoring schemes may significantly overcome inconsistencies between experimental groups. Clearly an appropriate pathway fitness scoring scheme has yet to be devised.
In summary, the analysis is sound, the results are clear, and the analyses of inconsistent data, as a means to obtain predictive biomarkers, remains a significant challenge. 
Benjamin Haibe-Kains
We thank Dr Covell for his constructive comments regarding our study. We are glad to hear that our PharmacoGx package is useful to reproduce our analysis results. The hope is that our package will enable other research groups to analyze and compare their own data with published large-scale pharmacogenomic datasets.
We agree with the reviewer that more investigation is required to better assess the technical vs biological variations for each of the pharmacological assays. Then biological variations could be leveraged, at the pathway level as the reviewer suggested, to define more robust biomarkers. projects linked to genomics data. The previous findings indicated that there is a lack of concordance between the two datasets that makes finding biomarkers of response difficult. Updating these studies with a wider array of methods in response to comments about the original article leaves largely the same result. Drug sensitivity profiles show significant variation between the two groups, likely due to differences in assay condition.
Safikhani
follow this analysis up with a discussion on how to improve the situation and here I have et al. some significant issues. The base argument is that the differences in platform are creating biases in the results and therefore the platforms need to be standardized. I think this is completely wrong. This makes sense if one platform were known to recapitulate response more accurately, but that is not true. We in vivo do not know if one platform is more physiologically relevant than another so the lack of standardization actually tells you something, it tells you when a predictor result is robust against biological context and is therefore more likely to work in new biological contexts. I would argue we need *more* variability in assays and platforms to broaden the scope of biological systems, not less.
Similarly, the statement is made that there is a 75% validation rate for eight drugs but that "this does not suggest that one can use these studies to find new, reproducible gene-drug associations...", I actually think it does, but perhaps I am missing a subtlety.
Finally, I think it is possible to set drug specific thresholds for each dataset. We have done this, I believe successfully, with datasets far smaller.
Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. This manuscript seeks to compare two large pharmacogenomics datasets (several hundred cancer cell lines screened against 15 common drugs) and evaluate their level of agreement via (1) the drug sensitivity values and (2) gene expression profiles of the cell lines. Broadly speaking, the value of these profiles is the discovery of (gene) biomarkers that could predict response of cells to the drugs. Previous efforts, including the authors' previous attempts, have had trouble with reproducibility. The authors have previously given harsh critiques regarding the reproducibility of the two datasets.
This manuscript is very important, and it has the potential to dissect sources of both agreement and disagreement that can be amplified or minimized in the future respectively. The reviewer also has little doubt that there is in fact disagreement between these two datasets and, moreover, it is significant enough as to interfere with the discovery of biomarkers. The reviewer also agrees with the authors that this is important to point out and understand, and the "call to arms" in the Discussion (the best written part of the manuscript) should certainly be listened to.
However, because this manuscript is very important , the cornerstones of the comparative analysis must be correct. The Supplemental Methods are near impossible to decipher and are littered with undefined terms, confusion in mathematical notation, poor equation formatting non-intuitive statements that do not assist the reader with understanding the numerous design choices (from throwing out poor quality data, to model fitting, to different measures of consistency). The Results section is not sufficient methodical to follow the argument of what does or does not represent ***statistically significant*** disagreement. Almost every paragraph until the conclusion presented serious challenges to this referee. They are included below. This is an important effort and the authors should return with an improved manuscript. Many of the co-authors are skilled mathematicians and they are strongly recommended to revisit every line of this co-authors are skilled mathematicians and they are strongly recommended to revisit every line of this manuscript to ensure correctness and to present with craftmanship. This is especially true in the Supplementary Methods that actually provide the "meat" of the methodology: this I believe must have been an oversight with this submission.
This manuscript needs to be published and I believe there are important lessons to be learnt here but there has to be a more focused, tighter argument to establish where there is disagreement and hypotheses as to why (in the Discussion) and what can be done about it. But the main issue here is that the basics of the paper are not solid, or at least they cannot be evaluated. The authors should be commended for the effort to be reproducible (in the sense they give the list of R packages used and their code) but that is only one aspect. The mathematics and statistics requires clarity and correctness. Terms such as "metric" should be used properly, and novel equations that are derived (e.g their "E" parameter) must be done so in a careful correct manner, with attempts made to justify these parameters (e.g \epsilon, \rho, 2*\epsilon, the $E$ parameter from the modified fit etc.
I would be happy to view a revised version of the manuscript and I hope that my comments aid in this important project. In the Methods "Cell line identity….", it is stated that 66 samples fell below threshold with a reference to the Supplementary methods. However I don't see anything in the supplementary methods that discusses this. Moreover in the text, it seems that you threw 8 cases away. This is confusing. pg 5. I'm not sure what you mean by "remain stable or decrease monotonically"? Do you just mean "monotonically non-increasing"? Please see comment regarding "Filtering of drug dose-response curves" form Supp Methods below. I think this really needs to be reworked, and I have to trust you guys here that you are doing the right thing.
"as exemplified…" depicted?
In Figure 4 , is it possible to relate this back to the choice of \rho, \epsilon and 2 \cdot \epsilon from the Supp Methods, or perhaps integration a version of this figure (but annotated) into the Supp Methods. In panel A, the grey area is a bit non-intuitive no? I would say that post 0.03, it's looking pretty good, and it's not measured in GDSC after that. However the first points are off.
I don't know what \epsilon or \rho are so it's hard to relate what is depicted in Figure 4 back to your model. Figure 1 (all the excluded comparisons), it seems like your criterion for excluding a comparison boils down cases where at least one of the curves has high variance, and the cutoff 2\epsilon I think is a constant independent of the distribution of points for either curve. I don't see in your equations how you encode that the sequence is monotonically non-increasing, or how "order" along the left to right sweep is incorporated.
When I look through Supplemental
Supp Methods Filtering of drug dose-response curves i +1^{st} -> (i+1)^{st}
It seems like there is a formatting problem here. In my pdf there is something like I"A squiggle after "in some large fraction ??? of the cases (1)." I guess that's supposed to be \rho right?
I'm not sure I understand this sentence "Our quality control …" Are you saying that \Delta_{i, i+1} < \epsilon in some fraction \phi of the cases? equation #2 below: I also have never seen set notation such as \{ \Delta_{i,i+1} | \Delta_{i,i+1} < \epsilon \}. Are you trying to say "given all the \Deltas that are less than \epsilon? So the vertical | means cardinality here right? But then the denominator has the cardinality of a value, or do you mean absolute value? What is \rho? It's undefined.
"Unfortunately …" The english is a bit rough -could be rephrased in terms of specificity and sensitive, I guess.
I don't understand the significance of the sentence "Consider, for instance, …" But in the main text, you say that it remains stable or decreases monotonically. Here it increases monotonically for many successive points, so this violates your model, no? I think that this subsection wants simply to spell out mathematically the thresholds and also provide some rationale for the parameters. I think the text doesn't really do a good job of establishing this rationale and needs work. Perhaps define the parameters precisely and then phrase the exposition in standard terms e.g. specific and sensitivity for different \epislon, etc.
Your equation (2) is inconsistent. In the text you specify \Sigma_{\forall i,j} \Delta_{i,j} but below your criterion seems to change to (the correct) $i < j$. It is also sufficient to write \Sigma{ i < j } \Delta_{i,j} and avoid the double summation.
You should probably define D_i in the text and not make the reader deduce it from the figure below
The comments here w.r.t. the Supplementary Methods also apply to the associated subsection of the Methods. The mathematical correctness of some comments needs attention. For example, it is not quite correct to say that the "curve fitting would have yielded erroneous results". The curve fitting is just that, curve fitting. It's not really an error. Then in the Methods, you claim to use this equation but this is inconsistent with the discussion in the Supplemental Methods (where you have an equation with this undefined parameter $E$).
The least-squares method using a three-parameter sigmoid model. I understand the intuition for this, but when I look through Supplementary File 2, I think there are a lot cases where this is perhaps not the correct pattern to assume (e.g. straight lines). Moreover, there are some very strange fits, for example, There is no derivation of this formula whatsoever. In fact, I don't see how this could be correct any longer. Couldn't this be expressed as mixture of two cell types, and y would be then a sort of weighted average? I really don't see how this was derived. This is a very central part of your paper (since the manuscript is measuring agreement) and therefore it needs to be bulletproof.
Please define "extant drug". Also HS is allowed to vary apparently but I don't see where it is then optimized in your analysis later on. This is confusing.
Consistency of Drug Sensitivity Data
Is the ABC method standard? Are there citations for this? You should probably define properly what you mean by the "insertion of the concentration range". Elsewhere it seems that you are referring to this as "common concentration range" e.g. SFig 2 More generally, isn't this a sort of (non-statistical) version of the Kolmogorov-Smirnoff test? I don't understand the definition of your three classes of drugs (no effect (AUC > 0.2); narrow effect AUC \leq 0.13 or broad affect AUC > 0.13). I don't see how this definition clearly delineates between "no effect" and "narrow effect". Figure 7 for example. To me it looks like there is excellent agreement except for perhaps the first row. Only paclitaxel fits into this "cyotoxic drug' category but for the life of me, I don't see where this is defined. The authors just defined three types of drugs (no effect, narrow effect and broad effect) but that's not what they are using here. I don't understand this. To me it simply seems to be that at low AUCs there is high variance in the last 3 distributions of the first line (17-AAG PD-0325901 and AZD6244), but actually they look like they pretty well agree at higher AUCs. I'm not sure what that means "and calculated the consistency of drug sensitivity data between studies using all common cases and only those that the data suggested were sensitive in at least on study.
Maybe a table would help, especially if each of these different objects were properly defined in the Methods/Supp Methods.
"Given that no single metric can capture all forms of consistency, …" So you add three more. I don't see "Given that no single metric can capture all forms of consistency, …" So you add three more. I don't see the point here. Why these three? and how is something like pearson \rho applied here. What is the vector? I would guess that Supp Figures should show the distribution of correlations for all three distributions so that we can look the different moments of these distributions (e.g. skew). In Figure 8 , there is a use of a * but how where these p-values estimated? Are these empirical estimations of the p-value?! I am totally confused here. You say in Figure 8 that panel A is "full data". But panel B is "sensitive cell lines". Where is this defined? the parentheses beside this in the figure caption? But why did you introduce this "broad, narrow, no effect" definitions only to redefine something else here?
I'm not sure I understand Supplemental Figure 11 . Is this just all probe groups for the Affy arrays, or how were features chosen? What is an "RNA-seq expression value"? how is this formed? rpm? Most importantly, I just don't know what the message is here, and if there is any statistics to support that statement.
I'm not sure I understand Figure 9 or what the take home message should be. I have a hard time understanding the labels along the x-axis in these figure. I just don't really know statistically how one can conclude that gene expression is more "consistent" than the drug sensitivity values. There could be a million things going on in those arrays. There are so many more datapoint and you have literally a hundred thousand probes that probably don't have an IQR > 1.5 on those arrays that "pump up" the correlation values, I would guess. What does this analysis mean?
Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. In panel A, the grey area is a bit non-intuitive no? I would say that post 0.03, it's looking pretty good, and it's not measured in GDSC after that. However the first points are off. Figure 1 (all the excluded comparisons) , it seems like your criterion for excluding a comparison boils down cases where at least one of the curves has high variance, and the cutoff 2\epsilon I think is a constant independent of the distribution of points for either curve. I don't see in your equations how you encode that the sequence is monotonically non-increasing, or how "order" along the left to right sweep is incorporated. 
In this panel the problematic curve is CCLE
When I look through Supplemental
Supp Methods Filtering of drug dose-response curves i +1^{st} -> (i+1)^{st}
Thanks for pointing this out, we corrected this in the revised manuscript. "Unfortunately …" The english is a bit rough -could be rephrased in terms of specificity and sensitivity, I guess.
We updated the manuscript accordingly.
I don't understand the significance of the sentence "Consider, for instance, …" But in the main text, you say that it remains stable or decreases monotonically. Here it increases monotonically for many successive points, so this violates your model, no?
Apply only equation (1) will not filter all the noisy cases and the curve explained in this sentence is one of those cases. Hence we also applied equations (2) and (3) to filter these remaining noisy curves. We clarified this in the revised manuscript.
I think that this subsection wants simply to spell out mathematically the thresholds and also provide some rationale for the parameters. I think the text doesn't really do a good job of establishing this rationale and needs work. Perhaps define the parameters precisely and then phrase the exposition in standard terms e.g. specific and sensitivity for different \epislon, etc. 
Your equation (2) is inconsistent.
In the text you specify \Sigma_{\forall i,j} \Delta_{i,j} but below your criterion seems to change to (the correct) $i < j$. It is also sufficient to write \Sigma{ i < j } \Delta_{i,j} and avoid the double summation. There is no derivation of this formula whatsoever. In fact, I don't see how this could be correct any longer. Couldn't this be expressed asmixture of two cell types, and y would be then a sort of weighted average? I really don't see how this was derived. This is a very central part of your paper (since the manuscript is measuring agreement) and therefore it needs to be bulletproof.
Corrected.
You should probably define
Please define "extant drug".Also HS is allowed to vary apparently but I don't see where it is then optimized in your analysis later on. This is confusing.
We thank the reviewer for his comments and we apologise for the lack of clarity of our Supplementary Methods. We have now rewritten this section to improve clarity and address all the reviewer's comments. Given the limited concentration range tested in high-throughput in vitro drug screening studies, such as GDSC nd CCLE, it is not possible to rule out that drug yielding no effect on cell viability could actually yield substantial effect at higher dose. However, these higher doses are likely to be clinically irrelevant. 
Consistency of Drug Sensitivity
It meant drugs for which there is a few sensitive cell lines in the CCLE and GDSC (narrow effect).
However, we changed it to targeted to avoid any confusion. I don't understand the definition of your three classes of drugs (no effect (AUC > 0.2); narrow effect AUC \leq 0.13 or broad affect AUC > 0.13). I don't see how this definition clearly delineates between "no effect" and "narrow effect".
We apologize for the confusion. We corrected the manuscript with the following definitions. Drugs with " To me it looks like there is excellent agreement except for perhaps the first row. Only paclitaxel fits into this "cyotoxic drug' category but for the life of me, I don't see where this is defined. The authors just defined three types of drugs (no effect, narrow effect and broad effect) but that's not what they are using here. I don't understand this. To me it simply seems to be that at low AUCs there is high variance in the last 3 distributions of the first line (17-AAG PD-0325901 and AZD6244), but actually they look like they pretty well agree at higher AUCs.
We agree with the reviewer that we have not been consistent in our definition of drugs with no, narrow and broad effect. This is now fixed in the updated manuscript. In Figure 7 ( 
